Targeting apoptosis: A new paradigm for the treatment of estrogen receptor-positive breast cancer Editorial
| Authors: | Drago, J. Z.; Chandarlapaty, S.; Jhaveri, K. |
| Title: | Targeting apoptosis: A new paradigm for the treatment of estrogen receptor-positive breast cancer |
| Abstract: | Standard treatment for estrogen receptor-positive metastatic breast cancer involves antiestrogen therapy used alone or in combination with inhibitors of CDK4/6 or mTOR; this approach works mechanistically by eliciting and reinforcing cell-cycle arrest. In this issue, Lok and colleagues diverge from this paradigm by combining the BCL2 inhibitor venetoclax with tamoxifen in a phase Ib clinical trial, building on preclinical work to demonstrate that targeting apoptosis could represent a promising new strategy in the treatment of breast cancer.See related article by Lok et al., p. 354. ©2019 American Association for Cancer Research. |
| Journal Title: | Cancer Discovery |
| Volume: | 9 |
| Issue: | 3 |
| ISSN: | 2159-8274 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-03-01 |
| Start Page: | 323 |
| End Page: | 325 |
| Language: | English |
| DOI: | 10.1158/2159-8290.Cd-19-0050 |
| PUBMED: | 30824486 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
277Chandarlapaty -
201Jhaveri -
27Drago
Related MSK Work